TherapeuticsMD (TXMD) Other Non-Current Liabilities (2012 - 2026)

TherapeuticsMD (TXMD) has reported Other Non-Current Liabilities for 9 consecutive years, with $873000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 4.93% year-over-year to $873000.0; the trailing twelve-month figure through Jun 2026 stood at $873000.0 (up 4.93% YoY), and the FY2025 full-year result was $873000.0, up 17.34% from the prior year.
• Other Non-Current Liabilities steadied at $873000.0 in Q2 2026 per TXMD's latest filing, from $873000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.2 million in Q1 2022 and bottomed at $554000.0 in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $855777.8 across 5 years, with a median of $851500.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 48.25% in 2022, then surged 114.62% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $1.1 million in 2022, then slumped by 42.55% to $636000.0 in 2023, then gained by 16.98% to $744000.0 in 2024, then rose by 17.34% to $873000.0 in 2025, then changed by 0.0% to $873000.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $873000.0, $873000.0, and $873000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.